media – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

What Are Buyers Looking For, and What Are Suppliers Focused On?

From September 16–18, CPHI & PMEC Shenzhen 2026 brought together pharmaceutical companies and industry professionals across APIs, excipients, finished formulations, pharmaceutical machinery, and other segments of the pharma value chain. The Drugdu.com team was on-site throughout the three-day event. We met familiar faces, connected with new companies across different sectors, talked with buyers looking for products and suppliers, and sat down with companies exploring new ways to expand their international business. After three days of conversations, one thing stood out: What matters is not simply how many people you meet at an exhibition, but what buyers and suppliers are actually looking for. Buyers Are Looking for More Than Products “Do you have suppliers for this product?” “Are there other Chinese manufacturers we can compare?” “Can we contact the manufacturer directly?” Many of our conversations with buyers started with a specific product. But finding the product is only the first step. ...
- Source: drugdu
- 40
- September 23, 2026
【EXPERT Q&A】How to apply for a medical device registration certificate?

Drugdu.com expert’s response: For medical device registration certificate application, the first step is not to immediately prepare a large stack of materials, but to determine which risk class the product belongs to. In China, medical devices are categorized into Class I, Class II and Class III based on their risk levels. Class I devices are subject to record-filing management, while Class II and Class III devices are subject to registration management. The “medical device registration certificate application” that enterprises usually refer to mainly targets Class II and Class III products. For domestic Class III devices, as well as imported Class II and Class III devices, the National Medical Products Administration (NMPA) is responsible for the review, evaluation and approval. Domestic Class II devices are generally registered under the charge of provincial drug regulatory authorities. After clarifying the product classification, you need to confirm the registration applicant and the production relationship. ...
- Source: drugdu
- 36
- September 23, 2026
Ho Chi Minh City Medical Devices, Analytical Biochemistry and Laboratory Equipment Exhibition

Organiser：Adpex JSC Time：September 22-24, 2026 Address：Lawrence S. Ting Building, 801 Nguyen Van Linh Parkway, District 7, Ho Chi Minh City, Vietnam Exhibition hall：Saigon Exhibition and Convention Center (SECC) Product range: ‌Medical Products Exhibition Area‌: Medical equipment and instruments, medical consumables, medical dressings, surgical equipment, ambulance equipment, diagnostic equipment and supplies, ophthalmic instruments and equipment, otolaryngology equipment, dental equipment and supplies, medical reagents and equipment, healthcare products and devices, medical institution and laboratory technical equipment, medical information and technical exchange, beauty instruments. ‌Analytical Instruments Exhibition Area‌: Optical analytical instruments, mass spectrometers, spectrometers, chromatographs, spectrum analyzers, frequency spectrum analyzers, electrochemical analytical instruments, radiographic analytical instruments, gas chromatographs, liquid chromatographs, thermal analytical instruments, portable instruments, surface analytical instruments, nuclear analytical instruments, elemental analytical instruments, process analytical instruments, compositional analytical instruments, injection analytical instruments, general-purpose analytical instruments. ‌Laboratory Equipment Exhibition Area‌: Laboratory instruments and equipment, laboratory automation and accessories, optical instruments and equipment, ...
- Source: drugdu
- 29
- September 22, 2026
【EXPERT Q&A】If the buyer requests COA, GMP and DMF at one time, do all the documents need to be sent?

Drugdu.com expert’s response: When exporting APIs, excipients, and peptide APIs, suppliers often receive inquiries like this. After asking about the product and price, the buyer quickly adds: “Please send COA, GMP and DMF.” Some suppliers may think the buyer is professional and immediately send all the documents they have. Others may be more cautious, worry about sensitive information, and simply reply: “Available.” Neither approach is ideal. When a buyer asks for COA, GMP and DMF at once, it may mean that this is not just a casual price inquiry. The buyer may already be checking whether the product can move forward to purchasing, registration, or supplier qualification. But what documents to send, and how much to share, still depends on the project stage. First, understand why the buyer needs these documents Even when buyers ask for the same documents — COA, GMP and DMF — their purpose may be different. Some buyers ...
- Source: drugdu
- 67
- September 21, 2026
【EXPERT Q&A】A Buyer Asked for Free Samples in the First Inquiry. Should You Send Them Right Away?

Drugdu.com expert’s response: If you’re working in the pharmaceutical or medical device export business, you’ve probably seen inquiries like this: Before discussing pricing or technical details, the buyer simply asks: “Can you provide free samples?” Some suppliers see this as a positive signal. They assume the buyer is ready to evaluate the product and hope that sending samples quickly will increase the chance of winning the order. Others become cautious immediately, worrying that the buyer is only looking for free samples with no real purchasing intention. In reality, both conclusions may be premature. A sample request shows that the buyer is interested enough to evaluate the product, but it doesn’t tell you why they need the sample, what they intend to do with it, or whether a commercial order is likely to follow. Instead of rushing to ship samples, it’s usually more valuable to clarify the buyer’s requirements first. ...
- Source: drugdu
- 103
- September 18, 2026
Novartis acquires Sironax’s blood-brain barrier delivery platform for $125 million

On September 16, Novartis announced the acquisition of biotechnology company Sironax for $125 million, gaining access to its proprietary blood-brain barrier (BBB) delivery platform technology. Sironax’s platform utilizes receptor-mediated transcytosis to efficiently deliver large molecule drugs (such as antibodies and gene therapies) into the central nervous system, addressing the longstanding challenge of large molecules being unable to cross the BBB. The technology platform is expected to significantly enhance Novartis’ drug development capabilities in central nervous system diseases, including Alzheimer’s disease, Parkinson’s disease, and neuro-oncology. This acquisition continues Novartis’ recent strategic investments in neuroscience and rare diseases. Blood-brain barrier delivery technology is considered a key enabling technology for next-generation CNS drug development. Source: https://tldrbio.tech/
- Source: drugdu
- 107
- September 17, 2026
IASO Bio’s in vivo CAR-T IASO208 receives FDA clinical trial clearance

On September 16, IASO Biotherapeutics announced that its investigational new drug application for IASO208, a CD20-targeting in vivo CAR-T product developed on its proprietary InTelliCAR platform, has received FDA clearance in the U.S. As the first lentiviral vector-based in vivo CAR-T product from China to receive FDA IND clearance, IASO208 will directly proceed to a Phase Ib study based on Chinese investigator-initiated trial data, targeting relapsed/refractory B-cell non-Hodgkin lymphoma. In vivo CAR-T is a next-generation cell therapy technology that eliminates the need for ex vivo T cell engineering, instead delivering vectors directly in patients to generate CAR-T cells in vivo. This approach has the potential to dramatically reduce treatment costs and timelines, moving cell therapy toward “off-the-shelf.” The FDA clearance for IASO208 signifies that China is competing on par with the international community in the in vivo CAR-T space, further deepening IASO Biotherapeutics’ internationalization in cell therapy. Source: http://m.toutiao.com/group/7686078944797311529/
- Source: drugdu
- 95
- September 17, 2026
NMPA accepts marketing registration application for Velsipity domestic manufacturing transfer

On September 17, Everest Medicines announced that CDE of the NMPA has accepted the marketing registration application for Velsipity (etrasimod arginine tablets) for the transfer of manufacturing from overseas to domestic production, and has granted Priority Review. Local production is expected to commence in 2027. Velsipity was approved by NMPA in February 2026 for adult patients with moderate to severe active ulcerative colitis (UC) who have an inadequate response, loss of response, or intolerance to conventional therapies or biologics. Source: https://finance.eastmoney.com/a/202609173876680142.html
- Source: drugdu
- 96
- September 17, 2026
Ziprasidone mesylate from SSY Group has been approved for registration as an active pharmaceutical ingredient.

On September 16, SSY Group announced that its ziprasidone mesylate has been approved by the NMPA of China for registration as an API used in marketed formulations. Ziprasidone mesylate is primarily used to treat acute agitation symptoms in patients with schizophrenia. According to the announcement, SSY Group has built a leading second-generation antipsychotic HPAPI platform in China, covering blonanserin, lurasidone, ziprasidone hydrochloride, and the newly approved ziprasidone mesylate. Source: https://finance.eastmoney.com/a/202609163876154835.html
- Source: drugdu
- 86
- September 17, 2026
Kanghong Pharmaceutical’s research on Shugan Jieyu Capsules won the first prize of the Science and Technology Award of the Chinese Pharmaceutical Association.

The 21st Chinese Pharmaceutical Association Science and Technology Award was presented at the 2026 Chinese Pharmaceutical Congress. The project “New Drug Creation and Industrial Innovation for Antidepressants Combining Traditional Chinese Medicine Syndromes,” in which Kanghong Pharmaceutical played a significant role, won the first prize. The Chinese Pharmaceutical Association Science and Technology Award was officially approved by the Ministry of Science and Technology in July 2005. It is sponsored by the Chinese Pharmaceutical Association and recognizes researchers and innovative achievements that have made major breakthroughs in pharmaceutical science. It is a highly prestigious and influential award in the domestic pharmaceutical field. Kanghong Pharmaceutical’s Shugan Jieyu Capsules are the core landmark achievement of this award-winning project. As the first approved traditional Chinese medicine for mild to moderate depression in China, this product is a Class II protected TCM variety and was recently included in the National Essential Medicines List (2026 Edition). Since ...
- Source: drugdu
- 82
- September 17, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.